

Special Issue

Salvage Therapy for Recurrent Prostate Cancer—Optimizing Oncological and Functional Outcomes

Message from the Guest Editors

Prostate cancer affects one in eight men in their lifetime. The current standard of care to treat localized prostate cancer is a radical prostatectomy or radiation therapy to the prostate. Following either of these therapies, prostate cancer may recur. Patients with localized recurrence may be a candidate for salvage radiation, salvage prostatectomy or whole gland ablation. In this special Issue, original research articles and reviews are welcome. Potential topics include but are not limited to the following:

- Work up of PSA recurrence following surgery/radiation.
- Interpretation of mpMRI after focal therapy.
- Role of salvage radical prostatectomy in patients with radiation resistant prostate cancer.
- Role of salvage cryoablation in patients with radiation resistant prostate cancer.
- Role of salvage HIFU in patients with radiation resistant prostate cancer.
- Salvage therapy for patients after focal therapy.
- Management of fistula from salvage therapy to the prostate.
- Incontinence after treatment for prostate cancer.
- Erectile dysfunction after treatment for prostate cancer.

We look forward to receiving your contributions.

Guest Editors

Dr. Wei Phin Tan

NYU Langone Health, New York, NY, USA

Dr. Amir H. Lebastchi

Department of Urology, University of Southern California, Los Angeles, CA, USA

Deadline for manuscript submissions

closed (20 October 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/139253

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)